Gilead Sciences (NASDAQ:GILD) Sets New 12-Month High at $84.30

Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) shares reached a new 52-week high on Monday . The stock traded as high as $84.30 and last traded at $84.25, with a volume of 32061 shares. The stock had previously closed at $83.62.

Analysts Set New Price Targets

Several research firms have recently weighed in on GILD. Piper Sandler upgraded shares of Gilead Sciences from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $79.00 to $96.00 in a research report on Friday, October 28th. BMO Capital Markets increased their price objective on shares of Gilead Sciences from $63.00 to $72.00 and gave the stock a “market perform” rating in a research report on Friday, October 28th. Jefferies Financial Group increased their price objective on shares of Gilead Sciences from $78.00 to $86.00 and gave the stock a “buy” rating in a research report on Friday, October 28th. Barclays upgraded shares of Gilead Sciences from an “underweight” rating to an “equal weight” rating and increased their price objective for the stock from $60.00 to $76.00 in a research report on Monday, October 31st. Finally, Robert W. Baird increased their price objective on shares of Gilead Sciences to $69.00 in a research report on Tuesday, November 1st. Eight analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $82.70.

Gilead Sciences Price Performance

The company has a debt-to-equity ratio of 1.14, a current ratio of 1.30 and a quick ratio of 1.16. The business’s fifty day moving average price is $71.28 and its 200-day moving average price is $65.64. The stock has a market capitalization of $106.90 billion, a price-to-earnings ratio of 32.16, a PEG ratio of 0.75 and a beta of 0.42.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 29th. Investors of record on Thursday, December 15th will be given a dividend of $0.73 per share. This represents a $2.92 dividend on an annualized basis and a dividend yield of 3.43%. The ex-dividend date is Wednesday, December 14th. Gilead Sciences’s payout ratio is currently 110.19%.

Insider Activity at Gilead Sciences

In related news, CAO Diane E. Wilfong sold 6,416 shares of the firm’s stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $83.50, for a total transaction of $535,736.00. Following the transaction, the chief accounting officer now directly owns 28,333 shares of the company’s stock, valued at $2,365,805.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Gilead Sciences news, CAO Diane E. Wilfong sold 16,255 shares of Gilead Sciences stock in a transaction dated Tuesday, November 1st. The shares were sold at an average price of $79.25, for a total value of $1,288,208.75. Following the sale, the chief accounting officer now owns 28,333 shares of the company’s stock, valued at $2,245,390.25. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Diane E. Wilfong sold 6,416 shares of Gilead Sciences stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $83.50, for a total transaction of $535,736.00. Following the completion of the sale, the chief accounting officer now directly owns 28,333 shares in the company, valued at approximately $2,365,805.50. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Institutional Trading of Gilead Sciences

Hedge funds have recently added to or reduced their stakes in the stock. JFS Wealth Advisors LLC raised its position in shares of Gilead Sciences by 68.1% in the third quarter. JFS Wealth Advisors LLC now owns 400 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 162 shares during the period. Pacifica Partners Inc. raised its position in shares of Gilead Sciences by 179.7% in the third quarter. Pacifica Partners Inc. now owns 414 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 266 shares during the period. Zullo Investment Group Inc. raised its position in shares of Gilead Sciences by 1,969.6% in the first quarter. Zullo Investment Group Inc. now owns 476 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 453 shares during the period. Horan Securities Inc. raised its position in shares of Gilead Sciences by 217.9% in the third quarter. Horan Securities Inc. now owns 461 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 316 shares during the period. Finally, Capital Advisors Ltd. LLC raised its position in shares of Gilead Sciences by 29.4% in the third quarter. Capital Advisors Ltd. LLC now owns 607 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 138 shares during the period. Institutional investors own 78.58% of the company’s stock.

Gilead Sciences Company Profile

(Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

See Also

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.